|
|
Pluristem’s PLX Cells May Effectively Treat Ischemic Stroke
Brain Research Journal Reports, HAIFA, ISRAEL. February 3, 2010
| Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder. Results will be published in the journal Brain Research (Brain Research, Feb. 22, Vol. 1315) under the title “Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats.” The study was conducted in collaboration with the Fraunhofer Institute for Immunology and Cell Therapy (IZI) in Leipzig, Germany.
The study indicates that in animals treated with PLX cells, there were significant differences to the control groups in the following parameters:
- Improvement in sensory and motor deficits
- Reduction in the development of the stroke lesion
- Increase in the production of glial nerve tissue
|
|
|
